Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade

YT Tsai, J Schlom, RN Donahue - Journal of Experimental & Clinical …, 2024 - Springer
The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly
influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical …

Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours

M Goswami, NJ Toney, SC Pitts… - Clinical and …, 2024 - Wiley Online Library
Background With the rapid adoption of immunotherapy for the treatment of cancer comes the
pressing need for readily accessible biomarkers to guide immunotherapeutic strategies and …

Peripheral CX3CR1+ T cells combined with PD-1 blockade therapy potentiates the anti-tumor efficacy for lung cancer

C Li, Z Zhang, Q Cai, Q Zhao, H Wu, JR Li, Y Liu… - …, 2024 - Taylor & Francis
Identifying tumor-relevant T cell subsets in the peripheral blood (PB) has become a potential
strategy for cancer treatment. However, the subset of PB that could be used to treat cancer …

Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC

N Kimura, Y Tsukita, R Ebina-Shibuya… - Cancer …, 2024 - content.iospress.com
BACKGROUND: Biomarkers predicting clinical outcomes of treating non-small cell lung
cancer (NSCLC) with combination of immune checkpoint inhibitors (ICIs) and chemotherapy …

Generation, transcriptomic states, and clinical relevance of CX3CR1+ CD8 T cells in melanoma

H Ishigaki, T Yamauchi, MD Long, T Hoki… - Cancer Research …, 2024 - AACR
Recent progress in single-cell profiling technologies has revealed significant phenotypic
and transcriptional heterogeneity in tumor-infiltrating CD8+ T cells. However, the transition …

[HTML][HTML] Spatial effects of infiltrating T cells on neighbouring cancer cells and prognosis in stage III CRC patients

M Azimi, S Cho, E Bozkurt, E McDonough, B Kisakol… - bioRxiv, 2024 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is one of the most frequently occurring cancers, but prognostic
biomarkers identifying patients at risk of recurrence are still lacking. In this study, we aimed …